Get started

Historicalminimum

GRIFOLS: Results day coming on Feb 26. Then to the moon?68.2% of GRIFOLS revenues come from the US and Canada. Covid19 cases there seem to be decreasing. The company is delaying more and more its deadline of results for the phase III of the inmunoglobulina antiCovid-19, now until spring 2021. If GRLS results are positive or better than expected (specially Q4 ones), I expect a jump from 21.61 to 26 in a matter of 2 weeks. The 2020 annual earnings are due on February 26. Grifols has a key support on 21.61 and then a structural support on 20.77. This week we'll see how it goes but as soon as it touches 21.61 is already a buy in my opinion and hold until Feb 26. Then depending on the results, sell or hold until its price objective recommendations which are around 30€. Note: RSI-14 is also below 30, so we might expect a change of trend sooner than later. Good luck traders and long-term investors!
BME:GRFLong
by alexinve
Prosegur Cash: Head and Shoulders and earningsH&S pattern and earnings outcome on July 31 may drag the price down to new historical minimum levels at 0.58, following long-term bearish channel. Also, second wave in Spain swelling may put pressure downwards on the stock price due to the company's main business: ATM's cash, which in covid19 days people are less keen on using physical money and prefer paying with card. However, Prosegur Cash is trying to keep floating capital with dividend reinvestments and buying its own capital. No analyst recommends to sell and 8 recommend to buy. Q1, CASH reduced profits 10.7% and made -3.9% sales. CASH also blames the currencies' effect to its earnings, so keep in mind that when covid exploded euro was up to 1.14 and now, after European Union took action with its funding 750.000 million, eurusd is up to 1.17. So watch out its Q2 earnings, but also get ready for Q3 in case Q2 are disappointing.
BME:CASHShort
by alexinve